Slingshot members are tracking this event:

Astellas (ALPMY) and Seagen (SGEN) Announce Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV (enfortumab vedotin-ejfv) in Advanced Urothelial Cancer

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Clinical Data The cohort is evaluating the antibody-drug conjugate PADCEV® (enfortumab vedotin-ejfv) for patients with locally advanced or metastatic urothelial cancer who have been previously treated with a PD-1/L1 inhibitor and have not received a platinum-containing chemotherapy and are ineligible for cisplatin. Results showed a 52 percent objective response rate (ORR) [95% Confidence Interval (CI): 40.8, 62.4] per blinded independent central review and a median duration of response of 10.9 months. The most frequently reported treatment-related adverse events Grade 3 or greater that occurred in more than 5 percent of patients were: neutropenia, rash, fatigue, increased lipase, diarrhea, decreased appetite, anemia and hyperglycemia. Data from cohort 2 of the trial will be submitted for presentation at an upcoming scientific congress and will be discussed with regulatory authorities.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 12, 2020
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Padcev, Enfortumab Vedotin-ejfv, Advanced Urothelial Cancer